ReviewArchivos de bronconeumologia2022
Short and Long-Term Impact of COVID-19 Infection on Previous Respiratory Diseases.
Review in Archivos de bronconeumologia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The Psychological and Physical Benefits of Progressive Muscle Relaxation in Chronic Respiratory Diseases: A Systematic Review.Medicina (Kaunas, Lithuania) · 2025Pooled it
- Pulmonary fibrosis complicated by lung cancer: bibliometric analysis from 2004 to 2024 - research status, trends and future directions.Frontiers in immunology · 2025Pooled it
- Risk factors of post-COVID-19 symptoms, a cross-sectional study in patients with asthma and chronic obstructive lung disease.NPJ primary care respiratory medicine · 2026Article
- Post-COVID-19 Muscle Weakness and Recovery Patterns After Mild-to-Moderate Infection: A Retrospective Analysis of a Structured Rehabilitation Program Using the MRC Scale.Healthcare (Basel, Switzerland) · 2026Article
- Delay in lung volume reduction surgery due to the COVID-19 pandemic: impact on patient performance and mortality.Journal of thoracic disease · 2025Article
- Burden of chronic respiratory diseases and their attributable risk factors in 204 countries and territories, 1990-2021: Results from the global burden of disease study 2021.Chinese medical journal pulmonary and critical care medicine · 2025Article
- A retrospective study of insurance coverage status and economic cost of rare diseases in Hainan Province.Scientific reports · 2025Article
- Prevalence and risk factors of long COVID-19 persisting for 2 years in Hainan Province: a population-based prospective study.Scientific reports · 2025Article
- The Great Mimicker: Pulmonary Adenocarcinoma with Interstitial Lung Disease-Like Presentation.European journal of case reports in internal medicine · 2025Article
- Increased circulating levels of SP-D and IL-10 are associated with the development of disease severity and pulmonary fibrosis in patients with COVID-19.Frontiers in immunology · 2025Article
- The Impact of COVID-19 on Migraine: The Patients' Perspective.Life (Basel, Switzerland) · 2024Article
- Musculoskeletal, Pulmonary, and Cardiovascular COVID-19 Sequelae in the Context of Firefighter Occupational Health: A Narrative Review.International journal of environmental research and public health · 2024Review
- COPD Self-Management: A Patient-Physician Perspective.Pulmonary therapy · 2024Article
- Article
- Long COVID in Children, Adults, and Vulnerable Populations: A Comprehensive Overview for an Integrated Approach.Diseases (Basel, Switzerland) · 2024Review
- SARS-CoV-2, periodontal pathogens, and host factors: The trinity of oral post-acute sequelae of COVID-19.Reviews in medical virology · 2024Review
- Short- and Long-Term Chest-CT Findings after Recovery from COVID-19: A Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2024Review
- The Role of Cytokines and Molecular Pathways in Lung Fibrosis Following SARS-CoV-2 Infection: A Physiopathologic (Re)view.Biomedicines · 2024Review
- ACE2: the node connecting the lung cancer and COVID-19.American journal of cancer research · 2024Review
- An analysis of exogenous harmful substance exposure as risk factors for COPD and hypertension co-morbidity using PSM.Frontiers in public health · 2024Article
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
On March 11, 2020, the World Health Organization declared Coronavirus Disease 2019 (COVID-19) a pandemic. Till now, it affected 452.4 million (Spain, 11.18 million) persons all over the world with a total of 6.04 million of deaths (Spain, 100,992). It is observed that 75% of hospitalized COVID-19 patients have at least one COVID-19 associated comorbidity. It was shown that people with underlying chronic illnesses are more likely to get it and grow seriously ill. Individuals with COVID-19 who have a past medical history of cardiovascular disorder, cancer, obesity, chronic lung disease, diabetes, or neurological disease had the worst prognosis and are more likely to develop acute respiratory distress syndrome or pneumonia. COVID-19 can affect the respiratory system in a variety of ways and across a spectrum of levels of disease severity, depending on a person's immune system, age and comorbidities. Symptoms can range from mild, such as cough, shortness of breath and fever, to critical disease, including respiratory failure, shock and multi-organ system failure. So, COVID-19 infection can cause overall worsening of these previous respiratory diseases, such as asthma, chronic obstructive pulmonary disease (COPD), interstitial lung disease, etc. This review aims to provide information on the impact of the COVID-19 disease on pre-existing lung comorbidities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.